Global Cancer Drug Therapy Market Size By Type (Targeted Therapy, Chemotherapy), By Application (Angiogenesis Inhibitors, mTOR Inhibitors), By Region, And Segment Forecasts, 2023 to 2032

The Global Cancer Drug Therapy Market was valued at USD 160.4 billion in 2023 and is projected to reach USD 302.7 billion by 2031, growing at a CAGR of 8.2% during the forecast period from 2023 to 2031. The market is witnessing robust growth driven by increasing cancer prevalence, advancements in targeted and immunotherapies, and the continuous pipeline of innovative oncology drugs. Rising healthcare expenditure, favorable reimbursement policies, and improved access to cancer diagnostics and treatments globally are further catalyzing market expansion.

Drivers

1. Rising Global Cancer Burden

The escalating incidence of cancer, fueled by aging populations and lifestyle changes, is a key driver. According to WHO, global cancer cases are expected to reach over 28 million by 2040, prompting increased demand for effective drug therapies.

2. Breakthroughs in Targeted and Immunotherapies

The emergence of immunotherapy, CAR-T cell therapy, and monoclonal antibodies has transformed cancer treatment paradigms. These precision-based treatments offer improved survival rates with fewer side effects, thereby increasing adoption.

3. Growing Healthcare Investments and Access

Expanding healthcare infrastructure, especially in emerging economies, coupled with government-led initiatives to improve oncology care, are enabling wider access to innovative cancer drugs.

Restraints

1. High Cost of Cancer Therapies

The cost of novel cancer drugs, particularly biologics and cell therapies, is often prohibitive. This poses affordability challenges, especially in low- and middle-income countries.

2. Complex Regulatory Approvals

Stringent clinical trial requirements and regulatory scrutiny can delay the entry of new drugs into the market, limiting timely access for patients.

Opportunities

1. Expanding Role of Personalized Medicine

Personalized oncology, where treatments are tailored based on genetic profiling and biomarkers, is gaining traction. This trend is unlocking new avenues for targeted therapy development.

2. Growth in Emerging Markets

Rapid healthcare development in countries like China, India, and Brazil presents significant opportunities. Increasing cancer screening programs and insurance coverage are driving drug uptake.

3. Digital Health Integration in Oncology

Tele-oncology, AI in diagnostics, and digital tracking of treatment responses are enhancing patient outcomes and drug efficacy, creating opportunities for tech-integrated drug solutions.

Market by System Type Insights

The market is segmented by therapy type, with Targeted Therapy accounting for the largest share in 2023. These therapies disrupt specific cancer cell mechanisms, offering higher efficacy and lower toxicity. However, Immunotherapy is expected to grow at the fastest rate during the forecast period, supported by ongoing research and promising clinical outcomes in difficult-to-treat cancers like melanoma and lung cancer.

Market by End-use Insights

Based on end use, Hospitals and Cancer Treatment Centers dominated the market in 2023. These facilities have the infrastructure and clinical expertise to administer complex therapies. Meanwhile, the Homecare segment is rapidly gaining ground, driven by oral cancer drugs and infusion therapies that enable treatment outside traditional healthcare settings.

Market by Regional Insights

North America led the market in 2023, thanks to high healthcare spending, early adoption of novel therapies, and strong presence of pharmaceutical giants. However, Asia-Pacific is projected to witness the fastest CAGR during the forecast period, fueled by large patient populations, rising cancer awareness, and increased healthcare investments.

Competitive Scenario

Key players in the Global Cancer Drug Therapy Market include:

Roche Holding AG

Bristol-Myers Squibb

Merck & Co., Inc.

Novartis AG

AstraZeneca

Johnson & Johnson

Pfizer Inc.

Amgen Inc.

Eli Lilly and Company

Gilead Sciences, Inc.

These companies are actively engaged in R&D collaborations, clinical trials, regulatory approvals, and strategic acquisitions. For instance:

In 2024, Merck’s Keytruda received expanded FDA approval for early-stage non-small cell lung cancer.

Roche acquired a biotech startup specializing in immune checkpoint inhibitors to strengthen its immuno-oncology portfolio.

AstraZeneca and Daiichi Sankyo launched a next-generation antibody-drug conjugate targeting HER2-low breast cancer.

Scope of Work – Global Cancer Drug Therapy Market

Key Market Developments

April 2024: Bristol-Myers Squibb entered a strategic partnership with a biotech firm for developing next-gen CAR-T therapies targeting hematologic malignancies.

January 2024: Gilead Sciences’ Trodelvy gained approval in multiple countries for metastatic triple-negative breast cancer.

September 2023: Novartis launched a new oral targeted therapy for advanced prostate cancer, enhancing treatment convenience and adherence.

FAQs

1) What is the current market size of the Global Cancer Drug Therapy Market?

The market was valued at USD 160.4 billion in 2023.

2) What is the major growth driver of the Global Cancer Drug Therapy Market?

The major driver is the increasing prevalence of cancer and advancements in immuno-oncology and targeted therapies.

3) Which is the largest region during the forecast period in the Global Cancer Drug Therapy Market?

North America is the largest region due to robust healthcare infrastructure and early access to innovative therapies.

4) Which segment accounted for the largest market share in Global Cancer Drug Therapy Market?

Targeted Therapy accounted for the largest market share in 2023.

5) Who are the key market players in the Global Cancer Drug Therapy Market?

Key players include Roche, Merck, Novartis, Bristol-Myers Squibb, AstraZeneca, and Pfizer.